TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19243767
Drug: NSAID (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily)
Study: 19243767
Drug: PG (misoprostol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG (misoprostol, 200 microg 3 times daily) with NSAID and omeprazole
Study: 16739326
Drug: 5'-DFUR (doxifluridine)
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (doxifluridine) at 800 mg/body daily for 3 years
Study: 16739326
Drug: 5'-DFUR (doxifluridine)
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (doxifluridine) at 800 mg/body daily for 1 year
Study: 16739326
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with gosereline acetate (3.6 mg/body, monthly) for pre-menopausal patients
Study: 16739326
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with tamoxifen (20 mg/day, daily) for post-menopausal patients
Study: 14710214
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (EMP) and vinblastine (VBL) combination chemotherapy
Study: 11846062
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose methotrexate (1 g/m2, day 1), fluorouracil (1.5 g/m2, day 1), leucovorin (15 mg/m2, days 2-4), and doxorubicin (30 mg/m2, day 15), repeated at a 28-day interval, followed by radical surgery
Study: 3936558
Drug: Sustained-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulations of valproic acid (VPA)
Study: 3936558
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet of valproic acid (VPA)
Study: 3936558
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) preparation of valproic acid (VPA)
Study: 30257756
Drug: 3 PRP
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 PRP injections in the subacromial space at 1-week intervals
Study: 30257756
Drug: Single depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single depot corticosteroid injection in the subacromial space
Study: 23672220
Drug: Acarbose chewable
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose chewable tablet
Study: 23672220
Drug: Acarbose treatment
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose treatment (control group)
Study: 18279686
Drug: EE-betadex clathrate/drsp
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE-betadex clathrate/drsp tablet
Study: 18279686
Drug: EE/drsp tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/drsp tablet
Study: 18279686
Drug: Microcrystalline suspension
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline suspension
Study: 12826042
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5)
Study: 10855533
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.2 pmol/l x kg(‐1) x min(‐1))
Study: 2004541
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 400 micrograms once daily
Study: 2004541
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 200 micrograms twice daily
Study: 30107003
Drug: Gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine treatment with high pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Study: 30107003
Drug: High pre-treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Study: 21277694
Drug: Gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine treatment
Study: 29933533
Drug: Sancai powder
Normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sancai powder and Metformin
Study: 22540957
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST) twice/week for 21 weeks (STW)
Study: 22540957
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (ST) twice/week for 21 weeks (STWx2)
Study: 22540957
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (STM) twice/week for 21 weeks
Study: 22540957
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training (STMx2) twice/week for 21 weeks
Study: 8874675
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (AP)
Study: 1343111
Drug: Felodipine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (oral solution, conventional tablets, extended release tablets)
Study: 1343111
Drug: Felodipine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (various formulations)
Study: 29587662
Drug: 0.5% colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% colchicine cream for 10 days
Study: 27515478
Drug: MAL-PDT (methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL-PDT (methyl aminolevulinate photodynamic therapy)
Study: 27508135
Drug: Apo‐Cetirizine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apo‐Cetirizine 10 mg tablet daily
Study: 27508135
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen of cetirizine 10 mg tablet, loratadine 10 mg tablet and chlorpheniramine 4 mg tablet, one tablet each day
Study: 23145952
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg initial dose, then 50 mg IV every 12 hrs)
Study: 23145952
Drug: Ampicillin-sulbactam (1.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (1.5-3 g IV every 6 hrs) or Amoxicillin-clavulanate (1.2 g IV every 6-8 hrs)
Study: 23145952
Drug: Ampicillin-sulbactam or
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam or Amoxicillin-clavulanate
Study: 18565418
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Management with Aspirin (ASA)
Study: 10457543
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral dose of SR 46349B (5-HT2 antagonist) administered three hours before bedtime
Study: 8527534
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 3 days)
Study: 8527534
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg four times daily for 7 days)
Study: 2254723
Drug: Regular Treatment
Normalized name: Midol Regular
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Treatment (RT)
Study: 6989436
Drug: Early injection
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early injection of insulin (30 minutes before breakfast)
Study: 6989436
Drug: Late injection
Normalized name: deoxycholate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late injection of insulin (5 minutes before breakfast)
Study: 6989436
Drug: Early injection
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early injection of insulin
Study: 6989436
Drug: Late injection
Normalized name: deoxycholate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late injection of insulin
Study: 6989436
Drug: Both injection
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both injection regimens
Study: 27716673
Drug: PARO robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARO robotic pet therapy
Study: 15930028
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg GTP
Study: 15930028
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg GTP
Study: 11044540
Drug: beta(2)-adrenergic agonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta(2)-adrenergic agonist therapy (clenbuterol)
Study: 11044540
Drug: physiological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological therapy (PT)
Study: 11044540
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of beta(2)-adrenergic agonist and PT
Study: 29182498
Drug: Cryogen-cooled monopolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryogen-cooled monopolar radiofrequency therapy (CMRF) at 90 J/cm2
Study: 29182498
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (≤1 J/cm2)
Study: 15533351
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue plus add-back therapy
Study: 3277588
Drug: One day
Normalized name: careone daytime nighttime severe cold and flu KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One day of cefonicid sodium therapy
Study: 3277588
Drug: Five days
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five days of cefonicid sodium therapy
Study: 3277588
Drug: Five days
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five days of cefamandole nafate therapy
Study: 29455298
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/day) and Exemestane (25 mg/day)
Study: 25331064
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue injection into the superior rectal artery
Study: 25442722
Drug: Buffered 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered 2% lidocaine with 1:80,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate
Study: 25442722
Drug: Nonbuffered 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbuffered 2% lidocaine with 1:80,000 epinephrine with 0.18 mL sterile distilled water
Study: 23678970
Drug: Standard Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Physical Therapy (Standard PT)
Study: 18446549
Drug: Acupuncture and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and/or interocclusal appliance therapy
Study: 11061985
Drug: Zafirlukast (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (40 mg oral)
Study: 9490579
Drug: 3% gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% gelatin (GEL)
Study: 3927690
Drug: Indomethacin after
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin after aspirin treatment
Study: 27003517
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injection (IRI)
Study: 11594442
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (100 mg caffeine) consumed by the test group when undeprived on days 1-4, tested when caffeine-deprived on day 5.
Study: 9767255
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin with vitamins E and C
Study: 9767255
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin C alone
Study: 9767255
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E alone
Study: 9767255
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin alone
Study: 9767255
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of vitamins E and C
Study: 8093132
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg twice daily)
Study: 2542193
Drug: Hyperfractionated (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU
Study: 30307966
Drug: Functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functionally orientated treatment based on the shortened dental arch (SDA) concept
Study: 24548447
Drug: Estimated drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated drug tolerated group (ERCC1 high expression or TOPO I low expression)
Study: 24548447
Drug: Estimated drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated drug sensitive group
Study: 18440181
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical care (claudication pharmacotherapy)
Study: 1936511
Drug: Regular gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular gel
Study: 6182412
Drug: Nicardipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 5 mg, 10 mg, 20 mg (each given three times daily for 1 week)
Study: 6182412
Drug: Nicardipine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (higher doses)
Study: 24419418
Drug: Maintenance pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance pemetrexed (500 mg/m)
Study: 20931804
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus metformin
Study: 19204305
Drug: Optimal pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacological therapy
Study: 15304029
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CT) alone
Study: 15304029
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CT) plus low-molecular-weight heparin (LMWH)
Study: 11236499
Drug: Immunotherapy (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (oral hyposensitization with mite allergens) in combination with ointment containing retinopalmitate and methyluracil
Study: 11236499
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment combined with the administration of placebo
Study: 8042821
Drug: Chlorambucil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.15 mg/kg body weight per day orally) and prednisone (three intravenous pulses of 1 g of methylprednisolone followed by oral prednisone at 0.5 mg/kg per day)
Study: 8042821
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (750 mg/m2 body surface area once every month for 6 months) and methylprednisolone (three intravenous 1-g pulses)
Study: 2892771
Drug: Propranolol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (doses reducing resting heart rate by 25%)
Study: 2892771
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral vitamin K)
Study: 19774436
Drug: 8.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.8 g/day of plant stanols
Study: 6932209
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravaginal PG F2 alpha
Study: 19432985
Drug: rhAPC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAPC treatment
Study: 14695390
Drug: Fixed duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed duration of contrast material injection for 25 seconds (group A)
Study: 14695390
Drug: Fixed duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed duration of contrast material injection for 35 seconds (group B)
Study: 14695390
Drug: Fixed injection
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed injection rate of 4.0 mL/sec (group C)
Study: 11720401
Drug: Pureed peach
Normalized name: Peach
DrugBank: Peach (DB10552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pureed peach with a thickening agent added
Study: 11720401
Drug: Pureed peach
Normalized name: Peach
DrugBank: Peach (DB10552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pureed peach with a thickening agent added and molded to look like peach slices
Study: 2889416
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg orally every 8 hours
Study: 22882399
Drug: Guaranteed methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaranteed methadone treatment admission upon release
Study: 22882399
Drug: Passive referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive referral to substance abuse treatment upon release
Study: 738078
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation of 40 mg frusemide and 600 mg slow-release potassium chloride
Study: 738078
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of 40 mg frusemide and 600 mg potassium chloride
Study: 29137091
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (RL)
Study: 29137091
Drug: Succinylated gelatin
Normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylated gelatin injection (Gel)
Study: 29137091
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline hydroxyethyl starch 40 injection (HS)
Study: 29137091
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (RL) and Succinylated gelatin injection (Gel)
Study: 25620547
Drug: Tangerine tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangerine tomato juice (10 mg lycopene, 94% cis)
Study: 25620547
Drug: Red tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red tomato juice (10 mg lycopene, 10% cis)
Study: 16958569
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH once daily (n = 32)
Study: 16958569
Drug: IR MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IR MPH three times daily (n = 32)
Study: 15151265
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg/day
Study: 15151265
Drug: Ramipril 1.25
Normalized name: ramipril 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 1.25 mg/day
Study: 11472790
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) + fluoxetine
Study: 9144122
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri
Study: 2951260
Drug: Fenflumizole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenflumizole 10 mg b.i.d. for four days followed by 10 mg daily for six days (Group I)
Study: 2951260
Drug: Fenflumizole 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenflumizole 20 mg b.i.d. for four days followed by 20 mg daily for six days (Group II)
Study: 23636236
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg elemental zinc/d)
Study: 20632667
Drug: Ephedrine 5
Normalized name: pseudoephedrine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 5 mg (group A; n = 31)
Study: 12922081
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial IgG antibody concentrations against pertussis toxin
Study: 8642163
Drug: 10 mcg
Normalized name: D400, 10 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg HBs vaccine (Recombivax, Merck, Sharp and Dohme)
Study: 8642163
Drug: 12 mcg
Normalized name: Thyrox 112 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mcg PreS2 + S vaccine
Study: 8642163
Drug: 24 mcg
Normalized name: Amitiza 24 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mcg PreS2 + S vaccine
Study: 1737453
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition plus human albumin 25 g/L as a continuous infusion
Study: 1737453
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (control)
Study: 3896964
Drug: +cyanidanol-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: +cyanidanol-3 (3 g daily)
Study: 22399076
Drug: BMS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS group therapy
Study: 15060238
Drug: No-treatment standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment standard care (control group)
Study: 3545461
Drug: L-Dopa plus
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Dopa plus benserazide
Study: 31808298
Drug: Low-dose SAR425899
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SAR425899 (0.03, 0.06 and 0.09 mg)
Study: 31808298
Drug: High-dose SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SAR425899 (0.06, 0.12 and 0.18 mg)
Study: 31808298
Drug: Low-dose SAR425899
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SAR425899
Study: 31808298
Drug: High-dose SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SAR425899
Study: 30183438
Drug: New adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: New adalimumab formulation